



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/676,260	10/02/2003	Hyung-seok Kang	912-41	3476

23117 7590 01/25/2007
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT	PAPER NUMBER
----------	--------------

1615

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/25/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/676,260	Applicant(s) KANG ET AL.	
	Examiner Gollamudi S. Kishore, Ph.D	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-17 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>11-30-04</u> . | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

Claims included in the prosecution are 1-17.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 11-17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The term, 'high concentration' is a relative term and therefore, it renders claim 11 indefinite.

According to claim 1, the formulation is a submicron liposome. However, claim 12 recites the higher range as 10 micrometer which is inconsistent with the term, 'submicron'.

'centella asiatica extract' might contain a triterpenoid, but it is not a triterpenoid itself as recited in claim 13.

It is unclear as to what 'pack' in claim 17 is intended to convey.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Art Unit: 1615

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Touitou (5,716,638) by itself or in combination Cauwenbergh (5,476,853).

Touitou discloses a method of preparation of liposomes containing active agents which includes terpenes. The method involves adding the lipophilic drug and Phospholipon in ethanol-propylene glycol either at room temperature or at 60 to 70 - degrees, adding to distilled water and TEA (triethanolamine) and cooling the mixture (abstract; col. 1, lines 8-32; col. 1, line 66 through col. 3, line 10; col. 4, lines 14-50; columns 5 and 6 and claims). Instant method differs from Touitou in the following way. In instant method the terpenoid is dispersed in polyol (propylene glycol) at 60-70 degrees to which TEA is added and then phospholipid solution in ethanol is added. To this mixture, water is then added. In Touitou, the lipophilic drug, phospholipid are added together in ethanol-propylene glycol mixture to which the TEA and water is added. Since the function of the base is to elevate the pH of a dispersion to alkaline values and since the addition of water to the phospholipid in the organic solvent in both Touitou and instant method, it would have been obvious to one of ordinary skill in the art at the time the invention was made to vary the steps in the method of Touitou and still expect the formation of the liposomes. Touitou also differs from instant method in the last step; that is, the addition of the acid to change the alkaline pH of the liposomal suspension. However, since the preparations of Touitou are meant for the topical application of skin, it would have been obvious to one of ordinary skill in the art to change the alkaline pH resulting from the addition of TEA in Touitou to neutral or near neutral pH by the

Art Unit: 1615

addition of an acid since these pH levels are compatible with skin. One of ordinary skill in the art would be motivated to change the alkaline pH of Touitou to pH of 5 to 7.5 since the reference of Cauwenbergh while disclosing liposomal skin formulations such as toilet waters and skin milk teaches that the final pH of 5 to 7.5 is preferable and this pH can be obtained by the addition of either a base or an acid or buffer such as citric acid or phosphoric acid or acetate buffer (abstract; col. 3, lines 37-65; Examples 4 and 5). Although Touitou does not teach specifically triterpenoids and claimed triterpenoids, since he teaches generic 'terpenes', it would have been obvious to one of ordinary skill in the art to use any terpene including claimed triterpenes since these are also lipophilic with a reasonable expectation of success.

5. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Touitou (5,716,638) by itself or in combination Cauwenbergh (5,476,853) in further combination with Delrieu (5,962,015).

The teachings of Touitou and Cauwenbergh have been discussed above.

Delrieu while disclosing stabilized liposome formulations teaches that compounds such as triethanolamine, a common cosmetic buffer, can be added to phospholipid starting materials during the preparation of the liposomes to prevent aggregation and provide some stability (abstract, col. 2, lines 2-5). Therefore, one of ordinary skill in the art to add TEA after instant step A with a reasonable expectation of success since Delrieu teaches that TEA can be added at any state of liposome preparation.

Art Unit: 1615

6. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Touitou (5,716,638) by itself or in combination Cauwenbergh (5,476,853) OR Touitou (5,716,638) by itself or in combination Cauwenbergh (5,476,853) in further combination with Delrieu (5,962,015) as set forth above, further in view of WO 01/17523 of record or vice versa: that is, WO 01/17523 in view of Touitou by itself or in combination with either Cauwenbergh or Cauwenbergh and Delrieu.

WO teaches liposomal skin compositions containing triterpenoid, ursolic acid (page 1, lines 20-31). The method of preparation involves dissolving ursolic acid, phosphatidylcholine in ethanol and then adding this mixture to water (Example 1). WO however, does not teach the inclusion of propylene glycol or prepare the liposomes by the addition of TEA.

The use of ursolic acid as the terpene in the generic teachings of Touitou or in the teachings of Touitou, Cauwenbergh and Delrieu with a reasonable expectation of success since WO teaches that ursolic acid can be encapsulated in liposomes for skin treatment. Alternately, the use of the method of Touitou in WO would have been obvious to one of ordinary skill in the art since according to Touitou the ethosomes prepared by the method taught are softer and have enhanced skin permeability for various compounds (col. 2, lines 3-24).

The reference of Tardy (2003/0091621 which teaches triethanolamine is abbreviated as TEA is cited of interest.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore, Ph.D whose telephone number is

Art Unit: 1615

(571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Woodward Michael can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Gollamudi S Kishore, Ph.D
Primary Examiner
Art Unit 1615

GSK